DARE
Dare Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+0.22%Oct 19, 2026, 12:56 UTC
Daré Bioscience announced premier sponsorship of Dare Bioscience, Inc. and the Dare Bioscience, Inc.’s continuing medical education program on managing menopause after breast cancer.
Source:Oct 13, 2026, 13:15 UTC
Dare Bioscience, Inc. launched a “CEO Corner” video series featuring CEO Sabrina Martucci Johnson to discuss the company’s women’s health portfolio, clinical pipeline and strategic priorities.
Source:Oct 2, 2026, 20:08 UTC
Dare Bioscience received a Nasdaq notice on September 28, 2026 that its common stock failed to maintain the $1.00 minimum bid price under Rule 5550(a)(2), giving it until March 29, 2027 to regain compliance.
Sep 28, 2026, 12:20 UTC
Daré Bioscience announced a new U.S. patent strengthening its DARE-HPV program, a potential first FDA-approved pharmacologic treatment for HPV infection.
Source:Sep 14, 2026, 12:50 UTC
Daré Bioscience announced the peer-reviewed publication of a Phase 1 study of its topical Sildenafil Cream, 3.6% in men, showing substantially lower systemic exposure versus oral sildenafil.
Source:Aug 31, 2026, 12:44 UTC
Daré Bioscience announced a new NIH funding award of approximately $908,000 to advance DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.
Source:Aug 26, 2026, 12:45 UTC
Daré Bioscience launched DARE to PLAY Sildenafil Cream, a 503B compounded version of its proprietary sildenafil cream formulation, while continuing to advance the product toward the FDA's 505(b)(2) regulatory pathway.
Source:Aug 17, 2026, 00:00 UTC
Dare Bioscience, Inc. signed a registered direct offering and concurrent private placement to raise approximately $6.0 million in gross proceeds, offering common stock, pre-funded warrants, and Series A and Series B common purchase warrants, with closing subject to customary conditions and stockholder approval for warrant exercise.
Aug 13, 2026, 00:00 UTC
Dare Bioscience, Inc. reported its Q2 2026 financial results, with total revenue of $0.2 million and a net loss of approximately $3.0 million, including a diluted EPS of -$0.20.
Source:Jul 1, 2026, 12:55 UTC
Daré Bioscience launched its product Flora Sync LF5 through its direct-to-consumer platform.
Source:Jun 12, 2026, 00:00 UTC
Dare Bioscience, Inc. elected Gregory W. Matz, CPA and Sabrina Martucci Johnson as Class III directors effective June 11, 2026.